Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-VISION: Empagliflozin in Heart Failure
NCT03332212Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in heart failure (HF), sponsored by Boehringer Ingelheim. Started Mar 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03332212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332212.